Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (181-190 of 462) with videos related to

Pageof 47
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative ColitisNeeraj Narula, Emily C L Wong, Jean-Frederic Colombel, et al.
Nature Reviews. Gastroenterology & Hepatology|September 28, 2017
Acute graft-versus-host disease of the gut: considerations for the gastroenterologistSteven Naymagon, Leonard Naymagon, Serre-Yu Wong, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2019
Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific regionShailja C Shah, Hamed Khalili, Chung-Yu Chen, et al.
ACR Open Rheumatology|February 2, 2021
Autoimmune and Chronic Inflammatory Disease Patients with COVID-19Ryan C Ungaro, Manasi Agrawal, Sarah Park, et al.
Inflammatory Bowel Diseases|May 12, 2019
The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical TrialAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Inflammatory Bowel Diseases|October 23, 2019
Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict RecurrenceRobert P Hirten, Ryan C Ungaro, Daniel Castaneda, et al.
Dermatology and Therapy|May 27, 2022
Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of ExposureChristopher E M Griffiths, Melinda Gooderham, Jean-Frederic Colombel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2021
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Journal of Crohn'S & Colitis|February 7, 2019
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical TrialsStephen Hanauer, William J Sandborn, Jean-Frederic Colombel, et al.
The American Journal of Gastroenterology|September 28, 2016
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With AdalimumabMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.
Pageof 47

Showing results (181-190 of 462) with videos related to

Sort By:
Pageof 47
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative ColitisNeeraj Narula, Emily C L Wong, Jean-Frederic Colombel, et al.
Nature Reviews. Gastroenterology & Hepatology|September 28, 2017
Acute graft-versus-host disease of the gut: considerations for the gastroenterologistSteven Naymagon, Leonard Naymagon, Serre-Yu Wong, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2019
Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific regionShailja C Shah, Hamed Khalili, Chung-Yu Chen, et al.
ACR Open Rheumatology|February 2, 2021
Autoimmune and Chronic Inflammatory Disease Patients with COVID-19Ryan C Ungaro, Manasi Agrawal, Sarah Park, et al.
Inflammatory Bowel Diseases|May 12, 2019
The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical TrialAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Inflammatory Bowel Diseases|October 23, 2019
Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict RecurrenceRobert P Hirten, Ryan C Ungaro, Daniel Castaneda, et al.
Dermatology and Therapy|May 27, 2022
Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of ExposureChristopher E M Griffiths, Melinda Gooderham, Jean-Frederic Colombel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2021
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Journal of Crohn'S & Colitis|February 7, 2019
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical TrialsStephen Hanauer, William J Sandborn, Jean-Frederic Colombel, et al.
The American Journal of Gastroenterology|September 28, 2016
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With AdalimumabMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.
Pageof 47